Search

Our group, the Laboratory of Experimental Cancer Immunogenomics, is a multi-disciplinary team of cancer scientists working at the intersection of genomics, molecular genetics, animal modeling, and biostatistical data sciences.

… Our group, the Laboratory of Experimental Cancer Immunogenomics, is a multi-disciplinary team of cancer scientists working at the intersection of  genomics ,  molecular genetics ,  animal modeling, and biostatistical data sciences . We are a mix of experienced researchers, postdoctoral fellows, clinical

Medical physicist John Humm focuses on noninvasive imaging of the tumor microenvironment using nuclear imaging methods.

… I am head of the nuclear medicine physics section, which supports research in PET/CT, targeted therapies, and molecular imaging. As both a medical and biophysicist, I investigate nuclear imaging methodologies to define tumor targets in terms of their metabolic and microenvironmental properties. I have

Chemical Biologist Minkui Luo develops cutting-edge tools, technologies and concepts to annotate functions of protein-posttranslational modifications and designs inhibitors for cancer therapies.

… The Luo Lab is interested in developing and leveraging novel approaches at the interface of chemistry and biology to annotate functional roles of epigenetic modulators. Epigenetic regulation is essential for maintaining cellular fates and its dysregulation has been associated with various diseases including

Physician-scientist Martin Weiser investigates the mechanisms underlying tumor spread and metastasis and how these mechanisms could be targeted.

… Our research investigates the natural history, molecular biology, and treatment response of cancers of the rectum and colon with the goal of personalizing therapy to reduce treatment toxicity, increase survival, and improve post-treatment quality of life.  We have built and tested clinical calculators

The Diver lab studies the physiological roles and molecular mechanisms of understudied membrane-embedded proteins with the goal of revealing novel therapeutic targets for diseases such as pain and cancer.

… Most drugs target membrane proteins, accessible on the surface of cells, to alter the transport of ions and molecules and the transduction of cellular signals. The Diver lab explores the biological functions and molecular mechanisms of understudied transmembrane protein families with the goal of revealing

The Shah lab focuses on the major topics of cancer evolution, single cell genomics and transcriptomics, mutational processes and prediction of drug response.

… The Shah lab focuses on the major topics of cancer evolution, single cell genomics and transcriptomics, mutational processes and prediction of drug response. We are interested in the major questions which underpin the cellular dynamics of cancer. Why do some cancer patients respond to treatment, while

The Greenbaum lab utilizes techniques from statistical physics, information theory, and evolutionary biology to better understand the role of self/non-self discrimination in tumor evolution, model response to immunotherapies, and quantify drivers of virus and cancer evolution.

… A main goal in the Greenbaum lab is to quantify how the immune system is activated and how it impacts tumor evolution. A particular focus in the lab is the role of repetitive elements in the genome, which mimic viral features and, just like viruses, evolve to escape immune surveillance. Dr. Greenbaum

Physician-scientist Liang Deng studies poxvirus interface with the immune system and the development of poxviruses as oncolytic and immunotherapy for cancers.

… Our laboratory is focused on understanding how poxviruses are detected by the host innate immune sensing mechanisms and how poxviruses evade host antiviral responses. We are also interested in the development of poxvirus-based oncolytic and immunotherapy for cancers including melanoma. Liang Deng, MD

Our team is focused on developing novel tools and approaches for the diagnosis and treatment of cancer using genomics as a guide.

… Our team is focused on developing novel tools and approaches for the diagnosis and treatment of cancer using genomics as a guide. Luis Diaz Jr., MD Head of the Division of Solid Tumor Oncology; Grayer Family Chair MD, University of Michigan Email [email protected] Office phone 646-888-4641

Molecular Pharmacology Program Member David Scheinberg focuses on the discovery and development of novel, specific immunotherapeutic agents and targeted nanodevices for cancer therapy.

… The overall goals of this laboratory are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes antibodies, targeted nano-devices, engineered cells, and active specific